nodes	percent_of_prediction	percent_of_DWPC	metapath
Bicalutamide—CYP2C19—Sorafenib—thyroid cancer	0.0938	0.216	CbGbCtD
Bicalutamide—CYP2C9—Sorafenib—thyroid cancer	0.078	0.179	CbGbCtD
Bicalutamide—CYP3A4—Vandetanib—thyroid cancer	0.0752	0.173	CbGbCtD
Bicalutamide—CYP2D6—Sorafenib—thyroid cancer	0.0713	0.164	CbGbCtD
Bicalutamide—CYP3A4—Sorafenib—thyroid cancer	0.0453	0.104	CbGbCtD
Bicalutamide—CYP2D6—Doxorubicin—thyroid cancer	0.0433	0.0996	CbGbCtD
Bicalutamide—CYP3A4—Doxorubicin—thyroid cancer	0.0275	0.0633	CbGbCtD
Bicalutamide—AR—Coregulation of Androgen receptor activity—NCOA4—thyroid cancer	0.00285	0.0814	CbGpPWpGaD
Bicalutamide—AR—Regulation of Androgen receptor activity—TRIM24—thyroid cancer	0.00242	0.069	CbGpPWpGaD
Bicalutamide—AR—Androgen receptor signaling pathway—NCOA4—thyroid cancer	0.00211	0.0602	CbGpPWpGaD
Bicalutamide—AR—Nuclear Receptors—THRB—thyroid cancer	0.00203	0.058	CbGpPWpGaD
Bicalutamide—AR—Regulation of nuclear SMAD2/3 signaling—CITED1—thyroid cancer	0.00202	0.0578	CbGpPWpGaD
Bicalutamide—AR—Nuclear Receptor transcription pathway—THRB—thyroid cancer	0.00161	0.0459	CbGpPWpGaD
Bicalutamide—AR—Regulation of nuclear beta catenin signaling and target gene transcription—TCF7L1—thyroid cancer	0.00103	0.0295	CbGpPWpGaD
Bicalutamide—AR—Nuclear Receptors—RXRA—thyroid cancer	0.000863	0.0247	CbGpPWpGaD
Bicalutamide—CYP2C19—Arachidonic acid metabolism—HPGD—thyroid cancer	0.000801	0.0229	CbGpPWpGaD
Bicalutamide—Dyspnoea—Sorafenib—thyroid cancer	0.000773	0.00146	CcSEcCtD
Bicalutamide—Nausea—Vandetanib—thyroid cancer	0.000763	0.00144	CcSEcCtD
Bicalutamide—Cramps of lower extremities—Doxorubicin—thyroid cancer	0.000763	0.00144	CcSEcCtD
Bicalutamide—Dyspepsia—Sorafenib—thyroid cancer	0.000763	0.00144	CcSEcCtD
Bicalutamide—Decreased appetite—Sorafenib—thyroid cancer	0.000754	0.00142	CcSEcCtD
Bicalutamide—Thrombophlebitis—Epirubicin—thyroid cancer	0.000753	0.00142	CcSEcCtD
Bicalutamide—Ecchymosis—Doxorubicin—thyroid cancer	0.000751	0.00142	CcSEcCtD
Bicalutamide—Neoplasm—Doxorubicin—thyroid cancer	0.000751	0.00142	CcSEcCtD
Bicalutamide—Blood alkaline phosphatase increased—Epirubicin—thyroid cancer	0.000749	0.00141	CcSEcCtD
Bicalutamide—Diabetes mellitus—Epirubicin—thyroid cancer	0.000749	0.00141	CcSEcCtD
Bicalutamide—Gastrointestinal disorder—Sorafenib—thyroid cancer	0.000748	0.00141	CcSEcCtD
Bicalutamide—Fatigue—Sorafenib—thyroid cancer	0.000747	0.00141	CcSEcCtD
Bicalutamide—Pain—Sorafenib—thyroid cancer	0.000741	0.0014	CcSEcCtD
Bicalutamide—Constipation—Sorafenib—thyroid cancer	0.000741	0.0014	CcSEcCtD
Bicalutamide—CYP2C9—Arachidonic acid metabolism—HPGD—thyroid cancer	0.00073	0.0209	CbGpPWpGaD
Bicalutamide—Hypertonia—Doxorubicin—thyroid cancer	0.000728	0.00137	CcSEcCtD
Bicalutamide—Hepatic failure—Epirubicin—thyroid cancer	0.000725	0.00137	CcSEcCtD
Bicalutamide—Abnormal vision—Doxorubicin—thyroid cancer	0.000725	0.00137	CcSEcCtD
Bicalutamide—Sepsis—Doxorubicin—thyroid cancer	0.000721	0.00136	CcSEcCtD
Bicalutamide—Cardiac failure congestive—Epirubicin—thyroid cancer	0.000719	0.00135	CcSEcCtD
Bicalutamide—Gastrointestinal pain—Sorafenib—thyroid cancer	0.000709	0.00134	CcSEcCtD
Bicalutamide—AR—SIDS Susceptibility Pathways—RET—thyroid cancer	0.000706	0.0202	CbGpPWpGaD
Bicalutamide—Hot flush—Epirubicin—thyroid cancer	0.000697	0.00131	CcSEcCtD
Bicalutamide—Thrombophlebitis—Doxorubicin—thyroid cancer	0.000697	0.00131	CcSEcCtD
Bicalutamide—Diabetes mellitus—Doxorubicin—thyroid cancer	0.000693	0.00131	CcSEcCtD
Bicalutamide—Blood alkaline phosphatase increased—Doxorubicin—thyroid cancer	0.000693	0.00131	CcSEcCtD
Bicalutamide—Menopausal symptoms—Epirubicin—thyroid cancer	0.000691	0.0013	CcSEcCtD
Bicalutamide—Urticaria—Sorafenib—thyroid cancer	0.000689	0.0013	CcSEcCtD
Bicalutamide—Abdominal pain—Sorafenib—thyroid cancer	0.000685	0.00129	CcSEcCtD
Bicalutamide—Body temperature increased—Sorafenib—thyroid cancer	0.000685	0.00129	CcSEcCtD
Bicalutamide—AR—Nuclear Receptor transcription pathway—RXRA—thyroid cancer	0.000682	0.0195	CbGpPWpGaD
Bicalutamide—Hepatic failure—Doxorubicin—thyroid cancer	0.000671	0.00126	CcSEcCtD
Bicalutamide—Cardiac failure—Epirubicin—thyroid cancer	0.000668	0.00126	CcSEcCtD
Bicalutamide—Hypoglycaemia—Epirubicin—thyroid cancer	0.000668	0.00126	CcSEcCtD
Bicalutamide—Cerebrovascular accident—Epirubicin—thyroid cancer	0.000665	0.00125	CcSEcCtD
Bicalutamide—Cardiac failure congestive—Doxorubicin—thyroid cancer	0.000665	0.00125	CcSEcCtD
Bicalutamide—AR—Regulation of Androgen receptor activity—RXRA—thyroid cancer	0.000661	0.0189	CbGpPWpGaD
Bicalutamide—AR—SIDS Susceptibility Pathways—THRB—thyroid cancer	0.000656	0.0188	CbGpPWpGaD
Bicalutamide—Hot flush—Doxorubicin—thyroid cancer	0.000645	0.00122	CcSEcCtD
Bicalutamide—Menopausal symptoms—Doxorubicin—thyroid cancer	0.000639	0.0012	CcSEcCtD
Bicalutamide—Hypersensitivity—Sorafenib—thyroid cancer	0.000639	0.0012	CcSEcCtD
Bicalutamide—CYP3A4—Liver X Receptor Pathway—RXRA—thyroid cancer	0.000631	0.018	CbGpPWpGaD
Bicalutamide—Face oedema—Epirubicin—thyroid cancer	0.000629	0.00119	CcSEcCtD
Bicalutamide—Asthenia—Sorafenib—thyroid cancer	0.000622	0.00117	CcSEcCtD
Bicalutamide—Cardiac arrest—Epirubicin—thyroid cancer	0.00062	0.00117	CcSEcCtD
Bicalutamide—Cardiac failure—Doxorubicin—thyroid cancer	0.000618	0.00116	CcSEcCtD
Bicalutamide—Hypoglycaemia—Doxorubicin—thyroid cancer	0.000618	0.00116	CcSEcCtD
Bicalutamide—Cerebrovascular accident—Doxorubicin—thyroid cancer	0.000615	0.00116	CcSEcCtD
Bicalutamide—Pruritus—Sorafenib—thyroid cancer	0.000613	0.00116	CcSEcCtD
Bicalutamide—Blood creatinine increased—Epirubicin—thyroid cancer	0.000611	0.00115	CcSEcCtD
Bicalutamide—Dehydration—Epirubicin—thyroid cancer	0.000606	0.00114	CcSEcCtD
Bicalutamide—Liver function test abnormal—Epirubicin—thyroid cancer	0.000602	0.00113	CcSEcCtD
Bicalutamide—Dry skin—Epirubicin—thyroid cancer	0.000597	0.00113	CcSEcCtD
Bicalutamide—Diarrhoea—Sorafenib—thyroid cancer	0.000593	0.00112	CcSEcCtD
Bicalutamide—Breast disorder—Epirubicin—thyroid cancer	0.000589	0.00111	CcSEcCtD
Bicalutamide—Aspartate aminotransferase increased—Epirubicin—thyroid cancer	0.000587	0.00111	CcSEcCtD
Bicalutamide—Face oedema—Doxorubicin—thyroid cancer	0.000582	0.0011	CcSEcCtD
Bicalutamide—Gastritis—Epirubicin—thyroid cancer	0.000577	0.00109	CcSEcCtD
Bicalutamide—Alanine aminotransferase increased—Epirubicin—thyroid cancer	0.000575	0.00108	CcSEcCtD
Bicalutamide—Muscular weakness—Epirubicin—thyroid cancer	0.000575	0.00108	CcSEcCtD
Bicalutamide—Cardiac arrest—Doxorubicin—thyroid cancer	0.000573	0.00108	CcSEcCtD
Bicalutamide—Dizziness—Sorafenib—thyroid cancer	0.000573	0.00108	CcSEcCtD
Bicalutamide—Blood creatinine increased—Doxorubicin—thyroid cancer	0.000565	0.00106	CcSEcCtD
Bicalutamide—Influenza—Epirubicin—thyroid cancer	0.000563	0.00106	CcSEcCtD
Bicalutamide—Asthma—Epirubicin—thyroid cancer	0.000563	0.00106	CcSEcCtD
Bicalutamide—Dysphagia—Epirubicin—thyroid cancer	0.000563	0.00106	CcSEcCtD
Bicalutamide—Dehydration—Doxorubicin—thyroid cancer	0.000561	0.00106	CcSEcCtD
Bicalutamide—Eosinophilia—Epirubicin—thyroid cancer	0.000558	0.00105	CcSEcCtD
Bicalutamide—Liver function test abnormal—Doxorubicin—thyroid cancer	0.000557	0.00105	CcSEcCtD
Bicalutamide—Dry skin—Doxorubicin—thyroid cancer	0.000553	0.00104	CcSEcCtD
Bicalutamide—Vomiting—Sorafenib—thyroid cancer	0.000551	0.00104	CcSEcCtD
Bicalutamide—Angina pectoris—Epirubicin—thyroid cancer	0.000549	0.00103	CcSEcCtD
Bicalutamide—Rash—Sorafenib—thyroid cancer	0.000547	0.00103	CcSEcCtD
Bicalutamide—Dermatitis—Sorafenib—thyroid cancer	0.000546	0.00103	CcSEcCtD
Bicalutamide—Breast disorder—Doxorubicin—thyroid cancer	0.000545	0.00103	CcSEcCtD
Bicalutamide—AR—Nuclear Receptors—PPARG—thyroid cancer	0.000545	0.0156	CbGpPWpGaD
Bicalutamide—Aspartate aminotransferase increased—Doxorubicin—thyroid cancer	0.000543	0.00102	CcSEcCtD
Bicalutamide—Headache—Sorafenib—thyroid cancer	0.000543	0.00102	CcSEcCtD
Bicalutamide—Bronchitis—Epirubicin—thyroid cancer	0.000542	0.00102	CcSEcCtD
Bicalutamide—AR—Notch-mediated HES/HEY network—HIF1A—thyroid cancer	0.000541	0.0154	CbGpPWpGaD
Bicalutamide—Gastritis—Doxorubicin—thyroid cancer	0.000534	0.00101	CcSEcCtD
Bicalutamide—Muscular weakness—Doxorubicin—thyroid cancer	0.000532	0.001	CcSEcCtD
Bicalutamide—Alanine aminotransferase increased—Doxorubicin—thyroid cancer	0.000532	0.001	CcSEcCtD
Bicalutamide—Neutropenia—Epirubicin—thyroid cancer	0.000527	0.000993	CcSEcCtD
Bicalutamide—Dysuria—Epirubicin—thyroid cancer	0.000527	0.000993	CcSEcCtD
Bicalutamide—Dysphagia—Doxorubicin—thyroid cancer	0.000521	0.000982	CcSEcCtD
Bicalutamide—Influenza—Doxorubicin—thyroid cancer	0.000521	0.000982	CcSEcCtD
Bicalutamide—Asthma—Doxorubicin—thyroid cancer	0.000521	0.000982	CcSEcCtD
Bicalutamide—Pollakiuria—Epirubicin—thyroid cancer	0.00052	0.000981	CcSEcCtD
Bicalutamide—Eosinophilia—Doxorubicin—thyroid cancer	0.000516	0.000973	CcSEcCtD
Bicalutamide—Nausea—Sorafenib—thyroid cancer	0.000515	0.00097	CcSEcCtD
Bicalutamide—Weight increased—Epirubicin—thyroid cancer	0.000513	0.000966	CcSEcCtD
Bicalutamide—Weight decreased—Epirubicin—thyroid cancer	0.00051	0.000961	CcSEcCtD
Bicalutamide—Hyperglycaemia—Epirubicin—thyroid cancer	0.000508	0.000958	CcSEcCtD
Bicalutamide—Angina pectoris—Doxorubicin—thyroid cancer	0.000508	0.000957	CcSEcCtD
Bicalutamide—Pneumonia—Epirubicin—thyroid cancer	0.000505	0.000952	CcSEcCtD
Bicalutamide—Bronchitis—Doxorubicin—thyroid cancer	0.000501	0.000945	CcSEcCtD
Bicalutamide—Neuropathy peripheral—Epirubicin—thyroid cancer	0.000492	0.000928	CcSEcCtD
Bicalutamide—Jaundice—Epirubicin—thyroid cancer	0.00049	0.000923	CcSEcCtD
Bicalutamide—Conjunctivitis—Epirubicin—thyroid cancer	0.000488	0.00092	CcSEcCtD
Bicalutamide—Urinary tract infection—Epirubicin—thyroid cancer	0.000488	0.00092	CcSEcCtD
Bicalutamide—Dysuria—Doxorubicin—thyroid cancer	0.000487	0.000919	CcSEcCtD
Bicalutamide—Neutropenia—Doxorubicin—thyroid cancer	0.000487	0.000919	CcSEcCtD
Bicalutamide—Sweating—Epirubicin—thyroid cancer	0.000482	0.000908	CcSEcCtD
Bicalutamide—Pollakiuria—Doxorubicin—thyroid cancer	0.000482	0.000908	CcSEcCtD
Bicalutamide—Haematuria—Epirubicin—thyroid cancer	0.000479	0.000903	CcSEcCtD
Bicalutamide—Hepatobiliary disease—Epirubicin—thyroid cancer	0.000475	0.000895	CcSEcCtD
Bicalutamide—Weight increased—Doxorubicin—thyroid cancer	0.000474	0.000894	CcSEcCtD
Bicalutamide—Epistaxis—Epirubicin—thyroid cancer	0.000474	0.000893	CcSEcCtD
Bicalutamide—Weight decreased—Doxorubicin—thyroid cancer	0.000472	0.000889	CcSEcCtD
Bicalutamide—Sinusitis—Epirubicin—thyroid cancer	0.000471	0.000888	CcSEcCtD
Bicalutamide—Hyperglycaemia—Doxorubicin—thyroid cancer	0.00047	0.000886	CcSEcCtD
Bicalutamide—Pneumonia—Doxorubicin—thyroid cancer	0.000467	0.000881	CcSEcCtD
Bicalutamide—Bradycardia—Epirubicin—thyroid cancer	0.000459	0.000865	CcSEcCtD
Bicalutamide—Neuropathy peripheral—Doxorubicin—thyroid cancer	0.000456	0.000859	CcSEcCtD
Bicalutamide—AR—Integrated Breast Cancer Pathway—TPR—thyroid cancer	0.000455	0.013	CbGpPWpGaD
Bicalutamide—Haemoglobin—Epirubicin—thyroid cancer	0.000453	0.000854	CcSEcCtD
Bicalutamide—Jaundice—Doxorubicin—thyroid cancer	0.000453	0.000854	CcSEcCtD
Bicalutamide—Rhinitis—Epirubicin—thyroid cancer	0.000452	0.000852	CcSEcCtD
Bicalutamide—Urinary tract infection—Doxorubicin—thyroid cancer	0.000452	0.000851	CcSEcCtD
Bicalutamide—Conjunctivitis—Doxorubicin—thyroid cancer	0.000452	0.000851	CcSEcCtD
Bicalutamide—Haemorrhage—Epirubicin—thyroid cancer	0.000451	0.00085	CcSEcCtD
Bicalutamide—Pharyngitis—Epirubicin—thyroid cancer	0.000448	0.000844	CcSEcCtD
Bicalutamide—Sweating—Doxorubicin—thyroid cancer	0.000446	0.00084	CcSEcCtD
Bicalutamide—Urinary tract disorder—Epirubicin—thyroid cancer	0.000445	0.000839	CcSEcCtD
Bicalutamide—Oedema peripheral—Epirubicin—thyroid cancer	0.000444	0.000837	CcSEcCtD
Bicalutamide—Haematuria—Doxorubicin—thyroid cancer	0.000443	0.000835	CcSEcCtD
Bicalutamide—Urethral disorder—Epirubicin—thyroid cancer	0.000442	0.000833	CcSEcCtD
Bicalutamide—Hepatobiliary disease—Doxorubicin—thyroid cancer	0.00044	0.000828	CcSEcCtD
Bicalutamide—Epistaxis—Doxorubicin—thyroid cancer	0.000438	0.000826	CcSEcCtD
Bicalutamide—AR—SIDS Susceptibility Pathways—PRKAR1A—thyroid cancer	0.000436	0.0125	CbGpPWpGaD
Bicalutamide—Sinusitis—Doxorubicin—thyroid cancer	0.000436	0.000822	CcSEcCtD
Bicalutamide—Visual impairment—Epirubicin—thyroid cancer	0.000435	0.000819	CcSEcCtD
Bicalutamide—AR—Nuclear Receptor transcription pathway—PPARG—thyroid cancer	0.000431	0.0123	CbGpPWpGaD
Bicalutamide—Bradycardia—Doxorubicin—thyroid cancer	0.000425	0.000801	CcSEcCtD
Bicalutamide—Haemoglobin—Doxorubicin—thyroid cancer	0.000419	0.00079	CcSEcCtD
Bicalutamide—Cardiac disorder—Epirubicin—thyroid cancer	0.000418	0.000789	CcSEcCtD
Bicalutamide—Rhinitis—Doxorubicin—thyroid cancer	0.000418	0.000788	CcSEcCtD
Bicalutamide—Haemorrhage—Doxorubicin—thyroid cancer	0.000417	0.000786	CcSEcCtD
Bicalutamide—Pharyngitis—Doxorubicin—thyroid cancer	0.000414	0.00078	CcSEcCtD
Bicalutamide—CYP2C19—Constitutive Androstane Receptor Pathway—RXRA—thyroid cancer	0.000414	0.0118	CbGpPWpGaD
Bicalutamide—Urinary tract disorder—Doxorubicin—thyroid cancer	0.000412	0.000777	CcSEcCtD
Bicalutamide—Oedema peripheral—Doxorubicin—thyroid cancer	0.000411	0.000775	CcSEcCtD
Bicalutamide—Angiopathy—Epirubicin—thyroid cancer	0.000409	0.000771	CcSEcCtD
Bicalutamide—Urethral disorder—Doxorubicin—thyroid cancer	0.000409	0.000771	CcSEcCtD
Bicalutamide—Immune system disorder—Epirubicin—thyroid cancer	0.000407	0.000768	CcSEcCtD
Bicalutamide—Mediastinal disorder—Epirubicin—thyroid cancer	0.000406	0.000766	CcSEcCtD
Bicalutamide—Chills—Epirubicin—thyroid cancer	0.000405	0.000763	CcSEcCtD
Bicalutamide—Arrhythmia—Epirubicin—thyroid cancer	0.000403	0.000759	CcSEcCtD
Bicalutamide—Visual impairment—Doxorubicin—thyroid cancer	0.000402	0.000758	CcSEcCtD
Bicalutamide—Alopecia—Epirubicin—thyroid cancer	0.000398	0.000751	CcSEcCtD
Bicalutamide—Mental disorder—Epirubicin—thyroid cancer	0.000395	0.000745	CcSEcCtD
Bicalutamide—Malnutrition—Epirubicin—thyroid cancer	0.000393	0.00074	CcSEcCtD
Bicalutamide—Cardiac disorder—Doxorubicin—thyroid cancer	0.000387	0.00073	CcSEcCtD
Bicalutamide—Flatulence—Epirubicin—thyroid cancer	0.000387	0.000729	CcSEcCtD
Bicalutamide—Tension—Epirubicin—thyroid cancer	0.000385	0.000726	CcSEcCtD
Bicalutamide—AR—Generic Transcription Pathway—TRIM33—thyroid cancer	0.000384	0.011	CbGpPWpGaD
Bicalutamide—Nervousness—Epirubicin—thyroid cancer	0.000381	0.000719	CcSEcCtD
Bicalutamide—Back pain—Epirubicin—thyroid cancer	0.00038	0.000716	CcSEcCtD
Bicalutamide—Angiopathy—Doxorubicin—thyroid cancer	0.000379	0.000713	CcSEcCtD
Bicalutamide—Muscle spasms—Epirubicin—thyroid cancer	0.000377	0.000711	CcSEcCtD
Bicalutamide—CYP3A4—Farnesoid X Receptor  Pathway—RXRA—thyroid cancer	0.000377	0.0108	CbGpPWpGaD
Bicalutamide—CYP2C9—Constitutive Androstane Receptor Pathway—RXRA—thyroid cancer	0.000377	0.0108	CbGpPWpGaD
Bicalutamide—Immune system disorder—Doxorubicin—thyroid cancer	0.000377	0.00071	CcSEcCtD
Bicalutamide—Mediastinal disorder—Doxorubicin—thyroid cancer	0.000376	0.000709	CcSEcCtD
Bicalutamide—Chills—Doxorubicin—thyroid cancer	0.000374	0.000706	CcSEcCtD
Bicalutamide—Arrhythmia—Doxorubicin—thyroid cancer	0.000373	0.000703	CcSEcCtD
Bicalutamide—AR—Regulation of nuclear beta catenin signaling and target gene transcription—TERT—thyroid cancer	0.000369	0.0106	CbGpPWpGaD
Bicalutamide—Alopecia—Doxorubicin—thyroid cancer	0.000369	0.000695	CcSEcCtD
Bicalutamide—Mental disorder—Doxorubicin—thyroid cancer	0.000366	0.000689	CcSEcCtD
Bicalutamide—CYP2C19—Metapathway biotransformation—CHST14—thyroid cancer	0.000365	0.0104	CbGpPWpGaD
Bicalutamide—Malnutrition—Doxorubicin—thyroid cancer	0.000363	0.000685	CcSEcCtD
Bicalutamide—Anaemia—Epirubicin—thyroid cancer	0.000363	0.000684	CcSEcCtD
Bicalutamide—Flatulence—Doxorubicin—thyroid cancer	0.000358	0.000675	CcSEcCtD
Bicalutamide—Tension—Doxorubicin—thyroid cancer	0.000356	0.000672	CcSEcCtD
Bicalutamide—Nervousness—Doxorubicin—thyroid cancer	0.000353	0.000665	CcSEcCtD
Bicalutamide—Syncope—Epirubicin—thyroid cancer	0.000352	0.000663	CcSEcCtD
Bicalutamide—Back pain—Doxorubicin—thyroid cancer	0.000351	0.000662	CcSEcCtD
Bicalutamide—Muscle spasms—Doxorubicin—thyroid cancer	0.000349	0.000658	CcSEcCtD
Bicalutamide—Loss of consciousness—Epirubicin—thyroid cancer	0.000345	0.00065	CcSEcCtD
Bicalutamide—AR—SIDS Susceptibility Pathways—SST—thyroid cancer	0.000345	0.00985	CbGpPWpGaD
Bicalutamide—Cough—Epirubicin—thyroid cancer	0.000343	0.000646	CcSEcCtD
Bicalutamide—Hypertension—Epirubicin—thyroid cancer	0.000339	0.000639	CcSEcCtD
Bicalutamide—Anaemia—Doxorubicin—thyroid cancer	0.000336	0.000633	CcSEcCtD
Bicalutamide—CYP2D6—Metapathway biotransformation—CHST14—thyroid cancer	0.000336	0.00959	CbGpPWpGaD
Bicalutamide—Chest pain—Epirubicin—thyroid cancer	0.000334	0.00063	CcSEcCtD
Bicalutamide—Myalgia—Epirubicin—thyroid cancer	0.000334	0.00063	CcSEcCtD
Bicalutamide—Anxiety—Epirubicin—thyroid cancer	0.000333	0.000628	CcSEcCtD
Bicalutamide—CYP2C9—Metapathway biotransformation—CHST14—thyroid cancer	0.000333	0.0095	CbGpPWpGaD
Bicalutamide—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—thyroid cancer	0.000332	0.000626	CcSEcCtD
Bicalutamide—Dry mouth—Epirubicin—thyroid cancer	0.000327	0.000616	CcSEcCtD
Bicalutamide—Syncope—Doxorubicin—thyroid cancer	0.000326	0.000614	CcSEcCtD
Bicalutamide—Confusional state—Epirubicin—thyroid cancer	0.000323	0.000609	CcSEcCtD
Bicalutamide—Oedema—Epirubicin—thyroid cancer	0.00032	0.000604	CcSEcCtD
Bicalutamide—Loss of consciousness—Doxorubicin—thyroid cancer	0.000319	0.000602	CcSEcCtD
Bicalutamide—Infection—Epirubicin—thyroid cancer	0.000318	0.0006	CcSEcCtD
Bicalutamide—Cough—Doxorubicin—thyroid cancer	0.000317	0.000597	CcSEcCtD
Bicalutamide—Shock—Epirubicin—thyroid cancer	0.000315	0.000594	CcSEcCtD
Bicalutamide—Nervous system disorder—Epirubicin—thyroid cancer	0.000314	0.000592	CcSEcCtD
Bicalutamide—Thrombocytopenia—Epirubicin—thyroid cancer	0.000314	0.000591	CcSEcCtD
Bicalutamide—Hypertension—Doxorubicin—thyroid cancer	0.000314	0.000591	CcSEcCtD
Bicalutamide—Skin disorder—Epirubicin—thyroid cancer	0.000311	0.000587	CcSEcCtD
Bicalutamide—Hyperhidrosis—Epirubicin—thyroid cancer	0.00031	0.000584	CcSEcCtD
Bicalutamide—Chest pain—Doxorubicin—thyroid cancer	0.000309	0.000583	CcSEcCtD
Bicalutamide—Myalgia—Doxorubicin—thyroid cancer	0.000309	0.000583	CcSEcCtD
Bicalutamide—Anxiety—Doxorubicin—thyroid cancer	0.000308	0.000581	CcSEcCtD
Bicalutamide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—thyroid cancer	0.000307	0.000579	CcSEcCtD
Bicalutamide—Anorexia—Epirubicin—thyroid cancer	0.000305	0.000576	CcSEcCtD
Bicalutamide—Dry mouth—Doxorubicin—thyroid cancer	0.000302	0.00057	CcSEcCtD
Bicalutamide—Confusional state—Doxorubicin—thyroid cancer	0.000299	0.000563	CcSEcCtD
Bicalutamide—Oedema—Doxorubicin—thyroid cancer	0.000296	0.000559	CcSEcCtD
Bicalutamide—Infection—Doxorubicin—thyroid cancer	0.000294	0.000555	CcSEcCtD
Bicalutamide—Musculoskeletal discomfort—Epirubicin—thyroid cancer	0.000292	0.00055	CcSEcCtD
Bicalutamide—Shock—Doxorubicin—thyroid cancer	0.000292	0.00055	CcSEcCtD
Bicalutamide—Nervous system disorder—Doxorubicin—thyroid cancer	0.000291	0.000548	CcSEcCtD
Bicalutamide—Thrombocytopenia—Doxorubicin—thyroid cancer	0.00029	0.000547	CcSEcCtD
Bicalutamide—Insomnia—Epirubicin—thyroid cancer	0.00029	0.000546	CcSEcCtD
Bicalutamide—Skin disorder—Doxorubicin—thyroid cancer	0.000288	0.000543	CcSEcCtD
Bicalutamide—Paraesthesia—Epirubicin—thyroid cancer	0.000288	0.000542	CcSEcCtD
Bicalutamide—AR—Nongenotropic Androgen signaling—HRAS—thyroid cancer	0.000287	0.0082	CbGpPWpGaD
Bicalutamide—Hyperhidrosis—Doxorubicin—thyroid cancer	0.000287	0.00054	CcSEcCtD
Bicalutamide—Dyspnoea—Epirubicin—thyroid cancer	0.000286	0.000538	CcSEcCtD
Bicalutamide—Somnolence—Epirubicin—thyroid cancer	0.000285	0.000537	CcSEcCtD
Bicalutamide—Anorexia—Doxorubicin—thyroid cancer	0.000283	0.000533	CcSEcCtD
Bicalutamide—Dyspepsia—Epirubicin—thyroid cancer	0.000282	0.000532	CcSEcCtD
Bicalutamide—Decreased appetite—Epirubicin—thyroid cancer	0.000278	0.000525	CcSEcCtD
Bicalutamide—AR—Generic Transcription Pathway—THRB—thyroid cancer	0.000277	0.00792	CbGpPWpGaD
Bicalutamide—Gastrointestinal disorder—Epirubicin—thyroid cancer	0.000277	0.000521	CcSEcCtD
Bicalutamide—Fatigue—Epirubicin—thyroid cancer	0.000276	0.000521	CcSEcCtD
Bicalutamide—Constipation—Epirubicin—thyroid cancer	0.000274	0.000516	CcSEcCtD
Bicalutamide—Pain—Epirubicin—thyroid cancer	0.000274	0.000516	CcSEcCtD
Bicalutamide—Musculoskeletal discomfort—Doxorubicin—thyroid cancer	0.00027	0.000509	CcSEcCtD
Bicalutamide—Insomnia—Doxorubicin—thyroid cancer	0.000268	0.000505	CcSEcCtD
Bicalutamide—Paraesthesia—Doxorubicin—thyroid cancer	0.000266	0.000502	CcSEcCtD
Bicalutamide—AR—Coregulation of Androgen receptor activity—CCND1—thyroid cancer	0.000265	0.00758	CbGpPWpGaD
Bicalutamide—Dyspnoea—Doxorubicin—thyroid cancer	0.000264	0.000498	CcSEcCtD
Bicalutamide—Feeling abnormal—Epirubicin—thyroid cancer	0.000264	0.000498	CcSEcCtD
Bicalutamide—Somnolence—Doxorubicin—thyroid cancer	0.000264	0.000497	CcSEcCtD
Bicalutamide—Gastrointestinal pain—Epirubicin—thyroid cancer	0.000262	0.000494	CcSEcCtD
Bicalutamide—Dyspepsia—Doxorubicin—thyroid cancer	0.000261	0.000492	CcSEcCtD
Bicalutamide—Decreased appetite—Doxorubicin—thyroid cancer	0.000258	0.000486	CcSEcCtD
Bicalutamide—Gastrointestinal disorder—Doxorubicin—thyroid cancer	0.000256	0.000482	CcSEcCtD
Bicalutamide—Fatigue—Doxorubicin—thyroid cancer	0.000256	0.000482	CcSEcCtD
Bicalutamide—Urticaria—Epirubicin—thyroid cancer	0.000255	0.00048	CcSEcCtD
Bicalutamide—AR—Nongenotropic Androgen signaling—AKT1—thyroid cancer	0.000254	0.00724	CbGpPWpGaD
Bicalutamide—Pain—Doxorubicin—thyroid cancer	0.000253	0.000478	CcSEcCtD
Bicalutamide—Constipation—Doxorubicin—thyroid cancer	0.000253	0.000478	CcSEcCtD
Bicalutamide—Abdominal pain—Epirubicin—thyroid cancer	0.000253	0.000477	CcSEcCtD
Bicalutamide—Body temperature increased—Epirubicin—thyroid cancer	0.000253	0.000477	CcSEcCtD
Bicalutamide—CYP2C19—Cytochrome P450 - arranged by substrate type—RXRA—thyroid cancer	0.00025	0.00715	CbGpPWpGaD
Bicalutamide—CYP3A4—Constitutive Androstane Receptor Pathway—RXRA—thyroid cancer	0.000249	0.0071	CbGpPWpGaD
Bicalutamide—Feeling abnormal—Doxorubicin—thyroid cancer	0.000244	0.00046	CcSEcCtD
Bicalutamide—Gastrointestinal pain—Doxorubicin—thyroid cancer	0.000242	0.000457	CcSEcCtD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—RXRA—thyroid cancer	0.000237	0.00678	CbGpPWpGaD
Bicalutamide—Hypersensitivity—Epirubicin—thyroid cancer	0.000236	0.000445	CcSEcCtD
Bicalutamide—Urticaria—Doxorubicin—thyroid cancer	0.000235	0.000444	CcSEcCtD
Bicalutamide—Abdominal pain—Doxorubicin—thyroid cancer	0.000234	0.000442	CcSEcCtD
Bicalutamide—Body temperature increased—Doxorubicin—thyroid cancer	0.000234	0.000442	CcSEcCtD
Bicalutamide—CYP2D6—Cytochrome P450 - arranged by substrate type—RXRA—thyroid cancer	0.00023	0.00657	CbGpPWpGaD
Bicalutamide—Asthenia—Epirubicin—thyroid cancer	0.00023	0.000433	CcSEcCtD
Bicalutamide—CYP2C9—Cytochrome P450 - arranged by substrate type—RXRA—thyroid cancer	0.000228	0.00652	CbGpPWpGaD
Bicalutamide—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—thyroid cancer	0.000227	0.00648	CbGpPWpGaD
Bicalutamide—Pruritus—Epirubicin—thyroid cancer	0.000227	0.000427	CcSEcCtD
Bicalutamide—CYP3A4—Metapathway biotransformation—CHST14—thyroid cancer	0.000219	0.00627	CbGpPWpGaD
Bicalutamide—Diarrhoea—Epirubicin—thyroid cancer	0.000219	0.000413	CcSEcCtD
Bicalutamide—Hypersensitivity—Doxorubicin—thyroid cancer	0.000218	0.000412	CcSEcCtD
Bicalutamide—AR—Regulation of nuclear beta catenin signaling and target gene transcription—CCND1—thyroid cancer	0.000214	0.0061	CbGpPWpGaD
Bicalutamide—Asthenia—Doxorubicin—thyroid cancer	0.000213	0.000401	CcSEcCtD
Bicalutamide—Dizziness—Epirubicin—thyroid cancer	0.000212	0.000399	CcSEcCtD
Bicalutamide—Pruritus—Doxorubicin—thyroid cancer	0.00021	0.000395	CcSEcCtD
Bicalutamide—AR—SIDS Susceptibility Pathways—HIF1A—thyroid cancer	0.000207	0.00592	CbGpPWpGaD
Bicalutamide—Vomiting—Epirubicin—thyroid cancer	0.000204	0.000384	CcSEcCtD
Bicalutamide—Diarrhoea—Doxorubicin—thyroid cancer	0.000203	0.000382	CcSEcCtD
Bicalutamide—CYP2C19—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	0.000203	0.00579	CbGpPWpGaD
Bicalutamide—Rash—Epirubicin—thyroid cancer	0.000202	0.000381	CcSEcCtD
Bicalutamide—Dermatitis—Epirubicin—thyroid cancer	0.000202	0.00038	CcSEcCtD
Bicalutamide—Headache—Epirubicin—thyroid cancer	0.000201	0.000378	CcSEcCtD
Bicalutamide—AR—Androgen receptor signaling pathway—CCND1—thyroid cancer	0.000196	0.0056	CbGpPWpGaD
Bicalutamide—Dizziness—Doxorubicin—thyroid cancer	0.000196	0.000369	CcSEcCtD
Bicalutamide—Nausea—Epirubicin—thyroid cancer	0.00019	0.000359	CcSEcCtD
Bicalutamide—AR—Androgen receptor signaling pathway—PTEN—thyroid cancer	0.000189	0.00541	CbGpPWpGaD
Bicalutamide—Vomiting—Doxorubicin—thyroid cancer	0.000188	0.000355	CcSEcCtD
Bicalutamide—Rash—Doxorubicin—thyroid cancer	0.000187	0.000352	CcSEcCtD
Bicalutamide—Dermatitis—Doxorubicin—thyroid cancer	0.000187	0.000352	CcSEcCtD
Bicalutamide—CYP2D6—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	0.000186	0.00533	CbGpPWpGaD
Bicalutamide—Headache—Doxorubicin—thyroid cancer	0.000186	0.00035	CcSEcCtD
Bicalutamide—CYP2C9—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	0.000185	0.00528	CbGpPWpGaD
Bicalutamide—AR—Gene Expression—TRIM33—thyroid cancer	0.000185	0.00528	CbGpPWpGaD
Bicalutamide—AR—Generic Transcription Pathway—MEN1—thyroid cancer	0.000176	0.00503	CbGpPWpGaD
Bicalutamide—Nausea—Doxorubicin—thyroid cancer	0.000176	0.000332	CcSEcCtD
Bicalutamide—AR—Integrated Breast Cancer Pathway—BRAF—thyroid cancer	0.000176	0.00503	CbGpPWpGaD
Bicalutamide—CYP3A4—Cytochrome P450 - arranged by substrate type—RXRA—thyroid cancer	0.00015	0.0043	CbGpPWpGaD
Bicalutamide—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—thyroid cancer	0.00015	0.00427	CbGpPWpGaD
Bicalutamide—AR—Coregulation of Androgen receptor activity—AKT1—thyroid cancer	0.000148	0.00422	CbGpPWpGaD
Bicalutamide—CYP2C19—Arachidonic acid metabolism—PTGS2—thyroid cancer	0.000144	0.00411	CbGpPWpGaD
Bicalutamide—AR—Gene Expression—THRB—thyroid cancer	0.000134	0.00381	CbGpPWpGaD
Bicalutamide—CYP2C9—Arachidonic acid metabolism—PTGS2—thyroid cancer	0.000131	0.00374	CbGpPWpGaD
Bicalutamide—AR—Integrated Breast Cancer Pathway—CCND1—thyroid cancer	0.000128	0.00367	CbGpPWpGaD
Bicalutamide—AR—Integrated Breast Cancer Pathway—PTEN—thyroid cancer	0.000124	0.00354	CbGpPWpGaD
Bicalutamide—CYP3A4—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	0.000122	0.00348	CbGpPWpGaD
Bicalutamide—AR—Generic Transcription Pathway—RXRA—thyroid cancer	0.000118	0.00337	CbGpPWpGaD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—PTGS2—thyroid cancer	0.000118	0.00337	CbGpPWpGaD
Bicalutamide—AR—Regulation of nuclear SMAD2/3 signaling—AKT1—thyroid cancer	0.000118	0.00336	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	0.000114	0.00327	CbGpPWpGaD
Bicalutamide—AR—Androgen receptor signaling pathway—AKT1—thyroid cancer	0.000109	0.00312	CbGpPWpGaD
Bicalutamide—CYP2C19—Biological oxidations—RXRA—thyroid cancer	0.000108	0.00308	CbGpPWpGaD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—CCND1—thyroid cancer	0.000106	0.00304	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	0.000104	0.00298	CbGpPWpGaD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—PTEN—thyroid cancer	0.000103	0.00294	CbGpPWpGaD
Bicalutamide—CYP2D6—Biological oxidations—RXRA—thyroid cancer	9.91e-05	0.00283	CbGpPWpGaD
Bicalutamide—CYP2C9—Biological oxidations—RXRA—thyroid cancer	9.82e-05	0.00281	CbGpPWpGaD
Bicalutamide—AR—Integrated Breast Cancer Pathway—KRAS—thyroid cancer	9.52e-05	0.00272	CbGpPWpGaD
Bicalutamide—AR—Gene Expression—TPR—thyroid cancer	9.02e-05	0.00258	CbGpPWpGaD
Bicalutamide—AR—Gene Expression—MEN1—thyroid cancer	8.48e-05	0.00242	CbGpPWpGaD
Bicalutamide—AR—Integrated Breast Cancer Pathway—TP53—thyroid cancer	8.46e-05	0.00242	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—MINPP1—thyroid cancer	7.91e-05	0.00226	CbGpPWpGaD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—KRAS—thyroid cancer	7.89e-05	0.00225	CbGpPWpGaD
Bicalutamide—AR—Generic Transcription Pathway—PPARG—thyroid cancer	7.44e-05	0.00213	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—MINPP1—thyroid cancer	7.28e-05	0.00208	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—MINPP1—thyroid cancer	7.22e-05	0.00206	CbGpPWpGaD
Bicalutamide—AR—Integrated Breast Cancer Pathway—AKT1—thyroid cancer	7.15e-05	0.00204	CbGpPWpGaD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—TP53—thyroid cancer	7.01e-05	0.002	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—NDUFA13—thyroid cancer	6.73e-05	0.00192	CbGpPWpGaD
Bicalutamide—CYP3A4—Biological oxidations—RXRA—thyroid cancer	6.48e-05	0.00185	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—CHST14—thyroid cancer	6.33e-05	0.00181	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—NDUFA13—thyroid cancer	6.19e-05	0.00177	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—NDUFA13—thyroid cancer	6.13e-05	0.00175	CbGpPWpGaD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—AKT1—thyroid cancer	5.92e-05	0.00169	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—CHST14—thyroid cancer	5.82e-05	0.00166	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—CHST14—thyroid cancer	5.77e-05	0.00165	CbGpPWpGaD
Bicalutamide—AR—Gene Expression—RXRA—thyroid cancer	5.67e-05	0.00162	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—HPGD—thyroid cancer	5.1e-05	0.00146	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—MINPP1—thyroid cancer	4.76e-05	0.00136	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—HPGD—thyroid cancer	4.69e-05	0.00134	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—HPGD—thyroid cancer	4.65e-05	0.00133	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	4.14e-05	0.00118	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—NDUFA13—thyroid cancer	4.05e-05	0.00116	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—CHST14—thyroid cancer	3.8e-05	0.00109	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	3.77e-05	0.00108	CbGpPWpGaD
Bicalutamide—AR—Gene Expression—PPARG—thyroid cancer	3.58e-05	0.00102	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—HPGD—thyroid cancer	3.07e-05	0.000876	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—TPR—thyroid cancer	2.93e-05	0.000837	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—PRKAR1A—thyroid cancer	2.88e-05	0.000823	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—TPR—thyroid cancer	2.69e-05	0.000769	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—TPR—thyroid cancer	2.67e-05	0.000763	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—PRKAR1A—thyroid cancer	2.65e-05	0.000757	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—PRKAR1A—thyroid cancer	2.63e-05	0.00075	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	2.61e-05	0.000746	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	2.38e-05	0.00068	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—SLC5A5—thyroid cancer	2.19e-05	0.000626	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	2.05e-05	0.000587	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—SLC5A5—thyroid cancer	2.02e-05	0.000576	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—SLC5A5—thyroid cancer	2e-05	0.000571	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	1.87e-05	0.000535	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—RXRA—thyroid cancer	1.84e-05	0.000526	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	1.79e-05	0.000512	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—TPR—thyroid cancer	1.76e-05	0.000503	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—PRKAR1A—thyroid cancer	1.73e-05	0.000495	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—RXRA—thyroid cancer	1.69e-05	0.000484	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—RXRA—thyroid cancer	1.68e-05	0.00048	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	1.63e-05	0.000467	CbGpPWpGaD
Bicalutamide—AR—Gene Expression—AKT1—thyroid cancer	1.42e-05	0.000405	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—SLC5A5—thyroid cancer	1.32e-05	0.000377	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—PPARG—thyroid cancer	1.16e-05	0.000332	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—RXRA—thyroid cancer	1.11e-05	0.000316	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—PPARG—thyroid cancer	1.07e-05	0.000306	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—PPARG—thyroid cancer	1.06e-05	0.000303	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—PTGS2—thyroid cancer	9.15e-06	0.000261	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—PTGS2—thyroid cancer	8.41e-06	0.00024	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—PTGS2—thyroid cancer	8.34e-06	0.000238	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—PTEN—thyroid cancer	7.98e-06	0.000228	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—PTEN—thyroid cancer	7.34e-06	0.00021	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—PTEN—thyroid cancer	7.27e-06	0.000208	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—PPARG—thyroid cancer	6.99e-06	0.0002	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—PTGS2—thyroid cancer	5.5e-06	0.000157	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—PTEN—thyroid cancer	4.8e-06	0.000137	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—AKT1—thyroid cancer	4.6e-06	0.000131	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—AKT1—thyroid cancer	4.23e-06	0.000121	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—AKT1—thyroid cancer	4.19e-06	0.00012	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—AKT1—thyroid cancer	2.77e-06	7.9e-05	CbGpPWpGaD
